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E-mail addresses: mmaitlan@medicine.bsd.uchicagoBackground: Kinase inhibition is an increasingly popular strategy for pharmacotherapy of human dis-
eases. Although many of these agents have been described as ‘‘targeted therapy”, they will typically inhi-
bit multiple kinases with varying potency. Pre-clinical model testing has not predicted the numerous
signiﬁcant toxicities identiﬁed during clinical development. The purpose of this study was to develop a
bioinformatics-based method to predict speciﬁc adverse events (AEs) in humans associated with the inhi-
bition of particular kinase targets (KTs).
Methods: The AE frequencies of protein kinase inhibitors (PKIs) were curated from three sources (Pub-
Med, Thompson Physician Desk Reference and PharmGKB), and afﬁnities of 38 PKIs for 317 kinases, rep-
resenting >50% of the predicted human kinome, were collected from published in vitro assay results. A
novel quantitative computational method was developed to predict associations between KTs and AEs
that included a whole panel of 71 AEs and 20 PKIs targeting 266 distinct kinases with Kd < 10 lM. The
method calculated an unbiased, kinome-wide association score via linear algebra on (i) the normalized
frequencies of AEs associated with 20 PKIs and (ii) the negative log-transformed dissociation constant
of kinases targeted by these PKIs. Finally, a reference standard was calculated by applying Fisher’s exact
test to the co-occurrence of indexed Pubmed terms (p 6 0.05, and manually veriﬁed) for AE and associ-
ated kinase targets (AE–KT) pairs from standard literature search techniques. We also evaluated the
enrichment of predictions between the quantitative method and the literature search by Fisher’s exact
testing.
Results: We identiﬁed signiﬁcant associations among already empirically well established pairs of AEs
(e.g. diarrhea and rash) and KTs (e.g. EGFR). The following less well recognized AE–KT pairs had similar
association scores: diarrhea-(DDR1;ERBB4), rash-ERBB4, and fatigue-(CSF1R;KIT). With no ﬁltering, the
association score identiﬁed 41 prioritized associations involving 7 AEs and 19 KTs. Among them, eight
associations were reported in the literature review. There were only 78 out of a total of 4522 AE–KT pairs
meeting the evaluation threshold, indicating a strong association between the predicted and the text
mined AE–KT pairs (p = 3  107). As many of these drugs remain in development, a larger volume of
more detailed data on AE–PKI associations is accessible only through non-public databases. These predic-
tion models will be reﬁned with these data and validated through dedicated prospective human studies.
Conclusion and future directions: Our in silico method can predict associations between kinase targets and
AE frequencies in human patients. Reﬁning this method should lead to improved clinical development of
protein kinase inhibitors, a large new class of therapeutics. http://www.lussierlab.org/publication/PAS/.
 2010 Elsevier Inc. All rights reserved.ll rights reserved.
inase target; AE, adverse event; Kd, dissociation constant.
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1.1. Motivation
Protein kinase inhibitors (PKIs) are a new class of drugs. Di-
rectly or indirectly, kinases regulate nearly every process of cells
and tissues. Scientists ﬁrst described the structure and function
of protein kinases through their studies of the molecular basis
of cancer. Many of the ﬁrst discovered ‘‘oncogenes” proved to
be mutant forms of the genes encoding protein kinases that re-
sulted in autonomous or dysregulated kinase activity. Based on
these concepts, PKIs were initially developed to treat cancer,
and the ﬁrst such drug to be approved for marketing by the
US Food and Drug Administration was imatinib (Gleevec™) for
treatment of chronic myelogenous leukemia (CML). Touted as
‘‘targeted therapy”, imatinib revolutionized treatment and prog-
nosis for this disease [1]. But characteristic of PKIs, imatinib
not only inhibits the Bcr-Abl oncogene speciﬁc to CML, but also
other kinase targets (KTs) such as c-Kit, and platelet derived
growth factor receptor alpha (PDGFRA). As imatinib was used
in increasing numbers of patients, unexpected adverse events
(AEs) such as hypophosphatemia [2] and cardiac dysfunction
[3] were identiﬁed. This pattern of inhibition of both intended
and unintended KTs with clear therapeutic beneﬁt limited by
unexpected AEs has been reproduced with every PKI approved
for widespread use. Many similar agents have failed or been
stalled during clinical development because of insufﬁcient bene-
ﬁt and unexpected toxicities. Better understanding of the physi-
ologic consequences of inhibiting speciﬁc KTs should lead to
development of safer cancer therapeutics, more effective combi-
nation treatments, and support the cross-purposing of these
drugs from cancer care for use in other diseases [4]. Speciﬁcally,
conﬁrming the absence of an adverse event is challenging in
conventional pre-clinical trials because these trials may not be
conducted in animal species exhibiting the AE. For example, ro-
dents may be used to deﬁned efﬁcacy; however, this species is
highly resistant to nausea and exotic animal species are required
to determine AEs that could occur in human. Consequently, the
development of a high throughput computational method over
in vitro assays may offer the opportunity to speciﬁc the require-
ments of speciﬁc pre-clinical assays to rule out putative AE iden-
tiﬁed in silico, accelerating the drug development process and
reducing costs by avoiding discovery of unexpected AEs of a
compound in clinical trials.1.2. Biological background
Protein kinases constitute much of the signaling pathways and
interactive cellular signaling networks. More than 500 protein ki-
nases are encoded in the human genome. The collection of these
evolutionarily conserved, modularly structured enzymes is re-
ferred to as the kinome [5]. Given the evolutionary history of these
proteins reﬂected in shared sequences, structures, and functions, it
is not surprising that drugs screened for capacity to inhibit speciﬁc
kinases inevitably seem also to inhibit some other kinases uninten-
tionally. Speciﬁcity has typically been assessed in in vitro cellular
assays. These assays are typically not standardized among labora-
tories and cross-reacting kinases might not be relevant to cellular
function or even be expressed at all in the particular tested cells.
Furthermore, the non-conserved sequences of kinase genes con-
tribute to the expression and functional differences in cellular sig-
naling that produce the metabolic and physiologic differences
among species, so animal toxicity ﬁndings do not consistently pre-
dict effects in humans. Consequently, the introduction of PKIs to
human subjects has led to novel observations not only for clinicaltherapeutics but for better understanding human molecular phys-
iology [4].
Although many methods have been developed [6,7] to predict
chemical structure/kinase inhibition relationships, there has been
no dedicated effort to associate inhibition of speciﬁc kinases with
physiologic consequences through systems analysis approaches.
Two major obstacles have been observed (1) the limited, labor-
intensive assessment of PKI speciﬁcity through cellular assays
without central laboratory standardization, and (2) limited concur-
rent comparisons of PKIs in clinical use or development on the
same platform. Recently, Zarrinkar and colleagues presented the
largest comparative analysis of PKI selectivity (including 38 PKIs)
with an unbiased in vitro kinome-wide binding assay [8]. Although
with acknowledged limitations, their data provide the opportunity
to cross-compare effects of many PKIs in clinical use and develop-
ment. The structured reporting of AEs in the clinical trials that have
tested these agents provides a database with which to infer AE–KT
relationships.
1.3. Bioinformatics background
Although there exist many computational approaches to predict
individual drug targets, few studies pertain to many targets. We
summarized in Table 1 those studies that access multiple-target
predictions (high throughput). Some excellent studies focused on
computationally predicting the target of drugs (bottom part of
the table), while others focused on their toxicities (middle part).
On the ﬁrst row, the present study, focuses on kinases, uses the
physical kinome map and provides an evaluation of adverse event
relationships, elements that contrast with the majority of other
studies.
Our methodological approach also differs from that of these
other publications. First, we used text mining technology to evalu-
ate our computationally predicted results. A few others undertak-
ing such large-scale approaches have incorporated text-mining and
natural language processing to unlock relevant data from disparate
and heterogeneous sources. For example, Kuhn et al. have created a
search tool for interactions of chemicals and proteins, coined
‘‘STITCH”, that consolidates chemicals and draws relationships be-
tween the chemicals and their activity data in cell lines, MeSH
assignments, and literature [17]. Textpresso and other text mining
approaches were used to curate the relationships between drugs
and genes [11,14]. However, simple text-mining would not provide
enough statistical power for a group of new drugs under active
clinical development, since there is insufﬁcient openly accessible
literature. For example, searching Pharmspresso by ‘‘EGFR side
effect” results in no match [14]. Second, we developed computa-
tional prediction analyses of toxicity of kinase inhibitors based
on kinome-wide association between kinase inhibitors and their
targets. Prior studies of adverse effects have mostly generated or
used molecular pathway atlases to assess structure–function cor-
relations in complex systems. For example, by understanding the
physiological pathways and potential binding partners of a candi-
date drug, it is theoretically possible to anticipate adverse events of
the candidate if the consequences of binding to these non-target
partners are known. One commercial provider, Cambridge Cell
Networks (CCNet) has created the ‘‘PathTox” tool that offers a se-
quence search in their pathway atlas that reports the probable sec-
ondary effects of candidates binding to speciﬁc partners [12].
Further, a research group at Pﬁzer has been able to forecast the ef-
fects of drugs on a large scale using computational techniques to
establish relationships between structure and function to predict
the probability of two drugs exhibiting similar system-wide effects
[13]. A recent study based on integration of data on gene–drug
interactions, gene-interaction and drug–drug similarity predicted
novel candidate genes that might affect inter-individual differ-
Table 1
The comparison with related studies.
Adverse
event-drug
Drug target prediction Protein target-toxicity PKI-speciﬁc input data size
Literature Physical
kinome
Literature Chemical
structure
Computational
prediction
Evaluation Kinome-
wide
analysis
Literature Computational
prediction
Evaluation Adverse
events (#)
Kinase
inhibitors
(#)
Kinase
targets
(#)
Studies focusing on kinaes toxicities
Present study j j j j C,M 71 20 266
General studies predicting target
toxicities (not focused on kinases)
Hansen 2009[9] j j B j 3 1* -
Bender A, et al. 2007[10] j j j j 166 - 0*
DART 2003[11] j j j 187 - -
Apic 2005 [12] j j - - -
Studies predicting drug targets, but
not their toxicities
Not
applicable
Fliri 2007 [13] j j C,B 5923 2* 168*
Garten 2009 [14] j 395* (a) 21* (b) 121* (c)
Liebovitch 2007 [15] j - - -
Campillos et al. 2008[16] j j j B 727 3* -
C = computational evaluation; B = biological validation; M = manual curation, #: count.
*: subset of gene targets with protein kinase activity (GO:0004672) or subset of drugs that are kinase inhibitors;
-: no speciﬁc detail about the input data.
(a): by searching the key words ‘‘side effect” in the Pharmspresso on line database (http://pharmspresso.stanford.edu/ygarten/Pharmspresso/html/index.html).
(b): by searching the key words ‘‘human”, ‘‘kinase” and ‘‘Inhibitor” in the Pharmspresso on line database.
(c): by searching the key words ‘‘human” and ‘‘kinase” in the Pharmspresso on line database.
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including one PKI geﬁtinib [9]. Third, though the feasibility of using
adverse events to reveal the molecular and genetic interactions
with drugs in humans has already been established, we are the ﬁrst
to develop computational methods focused on the complex, often
overlapping binding/inhibition proﬁles of PKIs speciﬁcally. A rele-
vant recent study uncovered 12 drug–target relationships by
means of predicting relationships using phenotypic adverse event
similarities; they further validated all of these relationships and
successfully conﬁrmed nine of the relationships using in vitro bind-
ing assays [16]. Recent computational studies predicted receptor
binding based on network features [18], or chemical similarities
[19]. In contrast, this study uses in vitro kinome and clinical trials
reports to predict mechanisms of toxicities attributable to the
off-target binding of kinase inhibitors. Others predicted combina-
tion of drugs with desired effects based on chemical structures of
drugs [15]. A pilot study predicted toxicity related targets by com-
bining drug off-targets binding and adverse reactions using Bayes-
ian methods [10], however, their resulting 70 targets contain no
kinase targets.
1.4. Rationale
To predict computationally the toxicities resulting from inhibi-
tion of speciﬁc KTs we developed a novel quantitative method
which was designed to be comprehensive and unbiased, including
all available information on AEs and PKIs. It provided a proof-of-
concept that AE–KT relationships can be predicted by analyzing
the speciﬁc AEs induced by multiple inhibitors and the propensity
of these inhibitors to bind speciﬁc KTs on a physical kinome map.
We then evaluated the prediction method by comparing the results
to evidence from literature mining.
1.5. Contribution
To our knowledge, we have performed the ﬁrst computational
prediction of toxicity of kinase inhibition using kinome-wide phys-
ical mapping. Our work contributed a table of PKIs with reported
adverse events and their prevalence.Fig. 1. Illustration of raw data and their relationship in this study.2. Methods
In this paper, we aim to offer a proof-of-concept by presenting a
signiﬁcant correlation between frequencies of adverse events and
kinome inhibition patterns through a survey of emerging kinase
inhibitors in three modules: (1) literature mining to generate
quantity mapping between PKIs and adverse events; (2) computa-
tionally predicting the signiﬁcant association between targets and
adverse events using two different methods; (3) evaluating the
predicted results by independent literature searching of co-occur-
rence and signiﬁcance estimation. Fig. 1 introduces the data and
their relationship and Fig. 2 demonstrates the three modules.
The frequencies of adverse events (AEs) associated with kinase
inhibitors were curated from three sources (Thompson Physician
Desk Reference, PharmGKB and PubMed). The dissociation con-
stants (Kd) of kinases were summarized from physico-chemical as-
says [8]. The computational method in this study considers all of
these data to predict the association between AEs and targets of ki-
nase inhibitors.
2.1. . Data organization
2.1.1. Kinome map collection and procession
The physical kinome map was summarized from novel PKI–KT
dissociation constant (Kd) data for 38 kinase inhibitors against apanel of 317 kinases [8]. Three steps were performed before statis-
tic computation: First, mutated targets were excluded, except for
those without assay for their non-mutation targets which were
GCN2, JAK1, JAK2 and JAK3, since the homologous gene targets
(mutated kinase) are repeated measures of the related targets
comparing to those of more independent genes. Second, 20 PKIs
having curated AEs with frequency of incidence in Supplementary
Table 1 were included. For example, albeit Flavopiridol is reported
to cause diarrhea in some patients, the accurate frequency could
not be assessed and enrolled into the Supplementary Table 1,
and thus were not included. Finally, we took a negative log-trans-
formation of all Kd values, because logarithm transformation re-
duces detection noise to an additive level and tends to convert
exponential distribution trends to normal distribution trends (Sup-
plementary Fig. 1).
In the module of data organization, two steps generated two
different associations used as the inputs to the ‘‘prediction of ki-
nase toxicity” module. In step z, a dissociation constant is found
in a physical kinome map, while in step z, drug adverse events
were curated from multiple sources. In the modules of prediction
of kinase toxicity (step z), a quantitative method was developed
to identify the prioritized AE–KT association scores (PAS). In the
evaluation (step z), Pubmed was mined to identify enriched AE–
KT pairs from a total of 4522 putative pairs among 17 AEs that have
more than ﬁve PKI repeats and 266 observed kinases. Then the
ﬁndings of the predictive method were evaluated against the text
mining results.
2.1.2. Curation for relationship between PKIs and adverse events from
various knowledge sources (Supplementary Table 1)
2.1.2.1. Adverse events source selection. To locate the adverse events
data for the collection of the 38 kinase inhibitors [8] with kinase
binding information, we reviewed a clinical pharmaceutical re-
source – Thomson Physician’s Desk Reference 2008 [20] (PDR), a
biomedical informatics resource – PharmGKB, as well as Med-
line-indexed primary research articles via PubMed. Given the het-
erogeneity of the PKI data reported in our sources, data found in
PDR and PharmGKB was given priority over any journal-derived
clinical data. When we failed to ﬁnd an agent in either PDR or Phar-
mGKB, the most recent journal articles with the most explicitly
quantiﬁed adverse event data were used. To cross-check the valid-
ity of the collected adverse event frequency values in PDR and
PharmGKB, we also compared the adverse event frequency data
for PKIs found in the electronic PKI database Facts and Compari-
sons (Version 4.0) for consistency.
2.1.2.2. Adverse event normalization. We normalized the frequency
values and the symptom/adverse event terms of the adverse event
data extracted from PharmGKB, PDR, and recent literature. We re-
Fig. 2. The study consists of three modules: data organization, computational prediction and computational evaluation.
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frequencies reported in the literature as a range or as different fre-
quencies from various sources, we took the mean value of the
range. Additionally, for frequencies presented in a series of com-
parative doses (e.g. 10 mg vs. 100 mg vs. 200 mg) we used the AE
frequencies associated with the highest dose. Second, to normalize
the AE terms we created logical AE terms to consolidate related AEs
(e.g. ‘‘Rash” encompasses ‘‘skin Rash”, ‘‘vesiculobullous rash”,
‘‘acneiform rash”, and ‘‘maculopapular rash”). For simpliﬁcation,
we hereafter refer to these normalized AE as AE.
2.1.2.3. Expected dverse event frequency in population. In practice, a
universal threshold indicating a frequency above that of placebo
for all adverse events was inappropriate. Indeed, certain adverse
events like headache or back pain occur at much higher incidence
in the population than that of neutropenia. Therefore, we reviewed
the literature to ﬁnd out the expected frequency, and then decided
a little severer threshold (generally by 50–100% above expected fre-
quency) for every adverse event. The literature sources comprise of:
(1) wrong diagnosis (http://www.wrongdiagnosis.com/p/pain/
prevalence-types.htm); (2) emedicine.com (http://www.emedi-
cine.com/emerg/topic233.htm); (3) population health metrics
(http://www.pophealthmetrics.com); (4) PKIs.com(http://ww.PKIs.
com) (5) DailyMed (http://dailymed.nlm.nih.gov); (6) Merck man-
ual online; (7) Google ‘‘adverse event” prevalence.
2.2. Computational prediction on associations between adverse events
and the kinome
The method was designed to take into account every piece of
evidence from the adverse events, kinases and kinome map. The
inputs were two quantitative association matrices: the curated
AE–PKI frequency matrix and the PKI–KT binding afﬁnity matrix,
respectively (Fig. 2).
We introduce deﬁnitions as follows: (dx), x = 1,. . .,p, denotes a set
of protein kinase inhibitor s(PKIs); (ty), y = 1,. . .,q, denotes a set of ki-
nase targets (KTs); and (ez), z = 1,. . .,r, is a set of adverse events (AEs).
Deﬁnition1. TheAE–KT associationmatrix A = (azy) consists of an
association score that reﬂects the association between the kinase
target tyand theadverse event ezwhich is a (r  q)dimensionmatrix.
Deﬁnition 2. The AE–PKI association matrix F = (fzx), a (r  p)
dimension matrix, consists of the frequency of normalized adverse
event ez for a PKI dx which were curated from three sources (Pub-
Med, Thompson Physician Desk Reference and PharmGKB).Deﬁnition 3. The PKI–KT relationship matrix K = (kxy), which is a
(p  q) dimension matrix, consists of an experimental dissociation
constant value (Kd value) for a PKI dx targeting ty that was reported
in literature [8].
2.3. Prioritized association scores (PAS)
The PAS method assumes that the toxicity of a single kinase can
be repeatedly observed by multiple PKIs targeting this kinase with
respects to both their combining afﬁnity and their AE frequencies.
By an association operation, the matrix multiplication, we scored
the AE–KT associations (Fig. 3) as:
A ¼ FlogðKÞ ¼ 
Xp
x¼1
ðfzxÞlogðkxyÞ ð1Þ
where F and K were the normalized frequency of AEs and the disso-
ciation constant of PKIs, respectively. The higher the score, the more
prioritized the association of the kinase with the corresponding ad-
verse event would be. Following the study of the false discovery
rate, a discovery threshold was set as the top (0.2% quantile) of all
observed scores in this study. Moreover, we traced back to identify
the PKIs that associated both to the kinase and the adverse event of
ﬁnding. These PKIs are much of interests because they should be
avoided of together using due to the higher possibility of inducing
the same adverse event. False discovery rates were computed on
each score by permutation resampling of K. Multiple comparisons
which were adjusted using the q-values [21,22]. R language source
of the Prioritized Association Scores method is available at http://
www.lussierlab.org/publication/PAS/.
The AE–KT prioritized association scores in matrix A were con-
structed by applying a matrix multiplication on the AE–PKI fre-
quency matrix F and the PKI–KT binding afﬁnity matrix K. A
prioritized AE–KT pair has an association score higher than the
top (0.2% quantile) of all observed scores (q-value < 21%).
2.4. Evaluation
2.4.1. Text mining of PubMed
To predict the adverse event of kinase by signiﬁcant co-occur-
rence in abstracts indexed in PubMed, we used Pubmatrix [23], a
multiplex literature mining tool. Let N be the totally records in
PubMed, we created a contingency table (Table 2) for each putative
pair of AE–KT: n2 is the number of abstracts containing a kinase t,
n3 is the number of abstracts about an adverse event e, and n1 is
Table 2
Contingency table for each AE–KT pair using text mining of Pubmed.
#Ref. include
kinase t
#Ref. not include
kinase t
P
#Ref. include AE e n1 n3-n1 n3
#Ref. not include AE e n2-n1 N-n2-n3 + n1 N-n3P
n2 N-n2 N
Fig. 3. The association scores identiﬁed prioritized AE–KT pairs were included to generate the output bipartite network.
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was applied to evaluate the signiﬁcance of association between
each pair of kinase target and adverse event [7,24]; and a gold
standard of unadjusted p 6 0.05 was set as signiﬁcant for a co-
occurrence. We further manually veriﬁed the computationally cor-
roborated pairs and rejected targets whose symbols appearing in
abstracts refer to other objects instead of genes, e.g. CIT is the
abbreviation for ‘‘city”, YES refers to ‘‘yes”,MET refers to ‘‘Methods”
or ‘‘metabolic equivalents”, Gak as institute name, and TEC is the
abbreviation for ‘‘toxigenic Escherichia coli” or ‘‘total eosinophil
counts” in many abstracts.
Using a Fisher’s exact test, we further evaluated the enrichment
(overlap) between the AE-and-KT co-occurrences in pubmed identi-
ﬁed by computational textmining and the AE–KT pairs predicted by
the association score method conducted over the kinome map.3. Results
3.1. Mapping PKIs and adverse events using literature curation
Karaman et al. successfully mapped an interaction for 38 PKIs
(drugs) across a panel of 317 kinases [8]. Our literature curation re-
sulted in 71 normalized AEs induced by 20 of these 38 PKIs from
181 literature-reported adverse drug activities (Fig. 2). The primary
analysis was performed on the minimal panel of the 266 distinct
kinases targeted by 20 PKIs, whereas the 20 PKIs had 71 reported
adverse events. Supplementary Table 1 gives the details of normal-
ized adverse events, their prevalence and the estimated threshold
of frequency. In the table, the adverse event ‘‘Asthenia” is merged
with ‘‘Fatigue” because of the similarity of these two categories;
conversely, the adverse event ‘‘Pain” is further subdivided into
‘‘Back Pain”, ‘‘Chest Pain” and ‘‘Pain” because of their different ra-
tios of incidences. A smaller panel of inputs for evaluation, the
17 AEs with more than ﬁve repeats of PKIs that target 266 distinct
kinases is described in Supplementary Table 2.3.2. Computational prediction of signiﬁcant associations between AEs
and kinase targets (methods, formula 1)
We identiﬁed 41 prioritized AE–KT associations among 19 tar-
gets and 7 adverse events using a threshold of the top of 0.2% quan-
tile of all 18,866 (71x266) scores (Supplementary Fig. 2 and Table3). Eight prioritized associations by PAS were also independently
related to signiﬁcant co-occurrences identiﬁed by text mining:
nausea to ERBB2, fatigue to VEGFR2, diarrhea to both KIT and EGFR,
rash to both EGFR and ERBB2, and asthenia to both ERGF and ERBB2
(red lines in Supplementary Fig. 2 and green lines in Supplemen-
tary Fig. 4). The predicted network of adverse events of kinase tar-
gets using association score. Fig. 4 is a bipartite network of the
identiﬁed associations summarized from the associations between
KTs and AEs after merging the vertices of similar AEs into one ver-
tex, which are nausea and vomiting, asthenia and fatigue.
Bipartite network of 41 prioritized AE–KT pairs with the top PAS
association scores (a score >0.2; the best 1/5 of 1% of all calculated
scores) consisting of seven distinct AEs and 19 distinct kinase tar-
gets. As shown in the plot, a wider line indicates a higher priority of
association. In additional, the predicted AE–KT associations by text
mining of PubMed (Fisher’s exact test p 6 0.05) are resented in red
color. In our evaluation using text mining, a Fisher’s exact test
showed a signiﬁcant (p = 3  107) association between the litera-
ture review among these 41 predicted AE–KT pairs. Pairs of similar
vertices (nausea and vomiting, asthenia and fatigue) were each
merged into a single vertex, respectively (For more details, see
Supplementary Fig. 2).
3.3. Evaluation
Independently, we searched PubMed using the on line tool
Pubmatrix [23] for every putative pair of kinase targets and adverse
events. For simpliﬁcation, we used a smaller panel of inputs, the 17
AEs with more than ﬁve repeats of PKIs that target 266 distinct ki-
nases. This panel evaluates the literature co-occurrence of 4522
(266  17) putative AE–KT pairs, which excludes only three cap-
tured AE–KT pairs from a total of 5320 (266  20) putative pairs
in PAS. As of Oct 21, 2008, there were a total of 19,028,626 (N) ab-
stracts indexed in PubMed. Among them, only 105 AE–KT pairs
meet the text mining gold standard (the unadjusted Fisher’s exact
tested p-value60.05). A stringent correction of p-values turned out
to be so conservative that many known associations between tar-
get of PKI and its side event were rejected. For example, the known
association between Nausea and ERBB2 [25], and between EGFR
and mucositis [26] will be rejected at a 5% level of adjusted p-val-
ues (Supplementary Table 4). Because our main goal is to generate
hypotheses, we chose to use the unadjusted FET p-value for a pri-
mary evaluation of the computational prediction. After manual
veriﬁcation, 27 pairs involving ﬁve targets, which were CIT, YES,
MET, Gak and TEC, were rejected due to their searched symbol rep-
resenting other objects instead of gene in the abstracts indexed in
PubMed (For details, see Supplementary Table 4). This kind of
rejection keeps the evaluation unbiased but removes a signiﬁcant
number of putative associations between side events and targets.
ImprovedMeSH term qualiﬁers or text mining approaches may im-
prove the accuracy of the results. Thereafter, 78 predicted AE–KT
Kinase
AE
Line Width : Prediction Score (a)
a > 0.2 (median q < 1%)
0.2 ≥ a > 0.113 (q ≤ 21%)
Line Color: Evaluation in Review of Literature
red Also found in Literature Review
grey Not found in Literature Review
Fig. 4. The predicted network of adverse events of kinase targets using association score.
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and kinase targets using computational text mining of literature
indexed in PubMed (Supplementary Fig. 3).
Eight out of 41 AE–KT pairs predicted using association score
were also predicted by literature review. A Fisher’s exact test
showed a strongly signiﬁcant association between the discovery
of our quantitatively computational method and the literature re-
view: p-value = 3  107.4. Discussion
Our study recapitulated well recognized associations between
AEs and widely used PKIs. The two strongest relationships cap-
tured are diarrhea, a recognized, mechanism-based adverse event
of epidermal growth factor receptor (EGFR) inhibition, and the
other common EGFR inhibitor-induced AE, rash. The rash caused
by EGFR kinase inhibitors has been associated with clinical re-
sponse for multiple cancers, and this serves as evidence that in-
tended KTs have both salutary and adverse effects where the
relationship was conﬁrmed by the PAS method [27–29]. Examina-
tion of these strongest relationships is useful for assessing our
methods development, making modiﬁcations for future analyses,
and generating hypotheses that might be easily validated on exist-
ing clinical specimens or data.
The cumulative adverse event data in this study are collected
from phase I, phase II, phase III, and other clinical investigations
of numerous kinase inhibitors, both those FDA approved and those
not yet completing clinical development; a larger sample than any
individual trial. These studies describe the full spectrum of adverse
events both drug-related and disease-related. In any single trial
(especially if this trial is not placebo controlled - the typical case
for oncology phase I trials) it is frequently not apparent which tox-
icities are reproducibly attributable to the drug, and it is certainly
not clear if the adverse events are due to the mechanism of action
of the drug or an ‘‘off-target” effect. The comparison of drugs with
overlapping and non-overlapping molecular binding properties
provides a rational approach to determining which adverse events,
dose-limiting or not, might be attributed to the inhibition of which
targets. Indeed, many of the so-called targeted kinase inhibitors
have been shown to target a wider spectrum of kinases than orig-
inally planned [30].
An unexpected and exciting ﬁnding is the identiﬁcation of the
CSF1R/fatigue and KIT/fatigue associations. As depicted on the ki-nome dendrogram [31], CSF1R, KIT and VEGFR2 are three kinases
with similar sequence and physical structure but with biological
roles important to different cell subsets. VEGFR2 is almost exclu-
sively expressed on endothelial cells and is activated in tumor
angiogenesis. Therefore this has been the primary target for several
new cancer therapeutics such as sunitinib and AMG-706 (now
known as motesanib). CSF1R plays a major role in granulocyte/
monocyte/macrophage development, signaling and regulation of
cytokine release and response. KIT signaling has been reported to
mediate various roles in different tissues, but is most prominently
involved in proliferation and differentiation of various hematopoi-
etic lineages and in mature mast cell and eosinophil signaling. The
agents developed to inhibit the structurally similar VEGFR2 tend to
have relatively high potency for CSF1R and KIT and fatigue is a com-
mon, sometimes dose-limiting adverse effect of these drugs.
Although we have identiﬁed a strong association between these ki-
nases and fatigue, it remains unclear whether one, two, or all three
of these KTs mediates the fatigue. If any of the three is differen-
tially associated, there will be the opportunity in either develop-
ment of new drugs or in administration of combinations of PKIs
to decrease the associated fatigue by either selectively eliminating
the offending KT afﬁnity or by selecting two PKIs that when added
together will maximize inhibition of the intended therapeutic KT,
while reducing the inhibition of the unintended, fatigue-inducing
target. Given the unbiased identiﬁcation of this AE–KT association
and its strength relative to the panel of relationships tested, our
clinical program has commenced studies of human circulating pro-
tein biomarkers for disruption of CSF1R signaling and validation
studies of the relationship between inhibition of CSF1R and fatigue
in cancer patients treated with PKI’s that target VEGFR2.
Mined facts from Pubmed used in the evaluation are speciﬁc for
each drug and, to our knowledge, only in very few speciﬁc cases
have been generalized to a group of drugs. While this is a limitation
of the evaluation, we believe this may be the ﬁrst high throughput
evaluation of PKI toxicities. While the gold standard of drug target
prediction, an older ﬁeld, is the biological validation in vitro, drug
toxicities predictions require a much more complex design for
two reasons: in vitro cellular studies cannot reﬂect more than a cel-
lular toxicity (animal models would be required for most clinical
toxicities such as rash, vomiting, etc.), and because of interspecies
differences in kinase structures and functions animals may fre-
quently not manifest the toxicities seen in humans. Finally, a spe-
ciﬁc drug target prediction is not generalized to a class of drug,
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ized ‘‘systems” property and requires a more comprehensive de-
sign for validation.4.1. Future studies and limitation
Adverse events occur in clinical studies where the tissue perfu-
sion of kinase inhibitor depends on its speciﬁc pharmacokinetics,
while the in vitro binding afﬁnity of a kinase receptor to a kinase
is measured as dissociation constant Kd. Our approach provides
calculations of AE and Kd jointly to create a compound score
(PAS) and control for multiplicity. Thus signiﬁcant PAS scores are
associated to a speciﬁc kinase, and may imply different underlying
Kd values for this kinase under different drug AE. It is a known fact
that each drug may have a speciﬁc pharmacokinetic proﬁle, and
thus the corresponding relevant in vitro Kd remains data driven
in our study. This kind of limitation in our study is also shared with
previous published efforts to use incidence of adverse events as a
means to infer previously unrecognized and untested drug/target
relationships [9–11,13,14,16]. An important advance upon the cur-
rent method will be to integrate data on physiologically relevant
pharmacokinetic and pharmacodynamic properties of different
drugs and targets. This will be most readily accomplished by ﬁrst
performing clinical validation of some of the associations identiﬁed
in this study.
We plan to conduct future studies to validate and extend the
method with toxicity data from clinical trials of novel kinase inhib-
itors sponsored by the National Cancer Institute. Better quantitative
gold standard data for adverse events might have been obtained
from the US adverse event report system (AERS) and the Canadian
adverse event reporting and learning system(CAERLS). Additionally,
a standardized ontology for adverse event is neededwhichmight be
taken from Health Canada’s Canadian Adverse Drug ReactionMoni-
toring Program (CADRMP, http://www.hc-sc.gc.ca/dhp-mps/me-
deff/databasdon/index-eng.php). Biological validation of any
speciﬁc target cannot be conducted using this method and would
be a complex pursuit. However, for strong candidates withmultiple
independent, but consistent data sources, we would consider a hu-
man clinical trial the best, gold standard approach to biological val-
idation. Additionally, we will explore additional models involving
pathways, multi-kinase effects, and other models of drug/kinase
inhibition beyond log-linear ones. However, by design, the physical
kinomemap limits thebreadthofourpredictions tokinase toxicities.
Arguably, other non-kinasetargetsmay exist and arebeyondour cal-
culations; however it will be challenging to distinguish non-target
speciﬁc effects from those of collective kinase inhibition. There is
increasing evidence that many PKIs aren’t as speciﬁc as the concept
of ‘‘targeted therapy” implies [30].5. Conclusion
Predicting toxicities of kinase inhibitors is an important prob-
lem for clinical development of new drugs. Current methods for
predicting toxicities mainly rely on pre-clinical cell and animal
studies [32]. Our in silico method can predict associations between
kinase targets and AE frequencies in human patients. This method
was controlled by false discovery, literature and expert review. Ex-
pert review further conﬁrmed that the method recapitulates exist-
ing empirical and mechanistic knowledge and provides novel and
clinically relevant insights (e.g. CSF1R/fatigue and KIT/fatigue). To
our knowledge, this is the ﬁrst study using kinome binding pat-
terns for predictions that proposes a novel Prioritized Association
Score and permutation resampling for increased sensitivity of re-
sults in spite of the scarcity of information about adverse effects
of kinase inhibitors.Reﬁning the method should lead to improved clinical develop-
ment of protein kinase inhibitors, a large new class of therapeutics
[4]. (1) As some AE–KT relationships will only be apparent at the
system physiology level, comprehensive screening for AE–KT rela-
tionships in patients exposed to these drugs provides the most
readily available method for detecting these relationships. (2) This
approach bypasses the species differences in drug pharmacokinet-
ics/pharmacodynamics that impair translation from animal mod-
els. (3) Knowing AE–KT relationships can improve the safety and
speed the completion of early trials of new kinase inhibitors. For
example, if inhibition of a particular kinase is associated with
hypertriglyceridemia, then determining the active dose range of a
novel PKI that blocks that KT could be accelerated by measuring
serum triglyceride elevations whether or not that KT is the in-
tended target. (4) This approach also can inform selection from
among the thousands of possible combinations of currently avail-
able PKI’s, those that have the greatest likelihood for non-overlap-
ping toxicity and hence a better therapeutic index. (5) Finally,
uncovering AE–KT relationships with novel PKI’s can reveal new
insight into the molecular physiology of the human body, leading
to the identiﬁcation of risk factors for bad outcomes for some drugs
and new clinical indications for others [4].
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